Moreover, pharmacological inhibition and degradation of EZH2 with IHMT-337 leads to the death of both DLBCL cell in vivo and TNBC primary patient cells and aberrant formation or growth of primary PDOs in vitro. The gene discussed is EZH2; the disease is diffuse large B-cell lymphoma.